Seizures is an indication for drug development with over 80 pipeline drugs currently active. According to GlobalData, preregistered drugs for Seizures have a 93.33% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Seizures compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Seizures overview
A seizure is a medical condition where the patient has a temporary, unstoppable surge of electrical brain activity. Affected brain cells uncontrollably fire signals to others around them, overloading the affected areas of the brain. That overload can cause a wide range of symptoms or effects, including abnormal sensations, passing out, and uncontrolled muscle movements. Up to 11% of people in the US will have at least one seizure during their life. Epilepsy is much less common: Between 1% and 3% of people in the US will develop epilepsy during their lifetime. Treatments for seizures vary widely, because the treatment for a provoked seizure depends almost entirely on its cause. Antiepileptic drugs are often the first treatment option for people experiencing multiple seizures. They target the signaling activities in specific brain cells and can effectively control seizures in approximately 70% of cases.
For a complete picture of PTSR and LoA scores for drugs in Seizures, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
